Skip to content

Loading your page…

Active substance · L01XM01

Enasidenib

On 2 registers3 medicines2 companies

See every medicineAsk Osler about it

Classification

Anatomical main groupLAntineoplastic and immunomodulating agents
Therapeutic subgroupL01Antineoplastic agents
Pharmacological subgroupL01XOther antineoplastic agents
Chemical subgroupL01XM
Chemical substanceL01XM01Enasidenib

Where it is registered

Each register with its number of medicines and a few of them.

Canada
Health Canada · 2 medicines · Historical list
- Idhifa50 MG · Tablet · Celgene INC
- Idhifa100 MG · Tablet · Celgene INC
United States
FDA · 1 medicine
- Idhifa100MG BASE, 50MG BASE · tablet · Bristol Myers Squibb

All medicines with Enasidenib

Every register, a page at a time. Strengths and packs are on each medicine’s page.

3 results

Medicine	Register	Strength	Form	Status	Holder
Idhifa	United States	100MG BASE, 50MG BASE	tablet	Marketed	Bristol Myers Squibb
Idhifa	Canada	50 MG	Tablet	Cancelled	Celgene INC
Idhifa	Canada	100 MG	Tablet	Cancelled	Celgene INC

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.